CompanyGraph
4DMedical Limited
4DX · ASX · Australia
Price data from its 4DX listing on CXA
4dmedical.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $4.14M, lower than 95% of all stocks globally
- PositionOperating margin is -929.7%, lower than 95% of its Medical Devices peers (median 7.3%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.41BAUD1.72B · vs all stocks (USD)
Revenue (TTM)
5.81MAUD4.14M · vs all stocks (USD)
Beta
1.97xvs all stocks
52-Week Change
651.43%vs all stocks
Market Capitalization
2.41BAUD1.72B · vs all stocks (USD)
Enterprise Value
1.96BAUD1.40B · vs all stocks (USD)
Forward P/E
-59.22xvs Medical Devices peers
Enterprise to Revenue
337.66xvs Medical Devices peers
Enterprise to EBITDA
-38.90xvs Medical Devices peers
Operating Margin
-929.72%vs Medical Devices peers
Return on Assets (TTM)
-26.14%vs Medical Devices peers
Revenue (TTM)
5.81MAUD4.14M · vs all stocks (USD)
Revenue per Share (TTM)
0.0120AUDUpdated Aug 20, 2026Quarterly Revenue Growth
-1.50%vs Medical Devices peers
Gross Profit (TTM)
5.34MAUD3.80M · vs all stocks (USD)
EBITDA (TTM)
-50.43MAUD-35.91M · vs all stocks (USD)
Net Income (TTM)
-172.93MAUD-123.11M · vs all stocks (USD)
Operating Cash Flow (TTM)
-32.99MAUD-23.49M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-117.52MAUD-83.67M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00AUDUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
5.78MAUDFY2025 · Jun 30, 2025Cost of Goods Sold
464.43KAUDFY2025 · Jun 30, 2025Gross Profit
5.31MAUDFY2025 · Jun 30, 2025Operating Income
-47.57MAUD-33.87M · vs all stocks (USD)
Pre-tax Income
-30.16MAUDFY2025 · Jun 30, 2025Income Tax Expense
-87.12KAUDFY2025 · Jun 30, 2025Net Income
-30.07MAUDFY2025 · Jun 30, 2025EBIT
-30.15MAUDFY2025 · Jun 30, 2025EBITDA (Income Statement)
-24.83MAUDFY2025 · Jun 30, 2025Research & Development
852.35KAUDFY2025 · Jun 30, 2025Selling, General & Administrative
34.80MAUDFY2025 · Jun 30, 2025Other Operating Expenses
11.91MAUDFY2025 · Jun 30, 2025Non-operating Interest Income
335.42KAUDFY2025 · Jun 30, 2025Non-operating Interest Expense
8.66KAUDFY2025 · Jun 30, 2025EPS (Basic)
-0.1400AUDFY2025 · Jun 30, 2025EPS (Diluted)
-0.1400AUDFY2025 · Jun 30, 2025Basic Shares Outstanding
214.78MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
214.78MSharesFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
6.88MAUDFY2025 · Jun 30, 2025Interest Paid
255.07KAUDFY2025 · Jun 30, 2025Capital Expenditures
-62.96KAUDFY2025 · Jun 30, 2025Net Intangibles (CF)
-197.43KAUDFY2025 · Jun 30, 2025Net Acquisitions
-297.38KAUDFY2025 · Jun 30, 2025Other Investing Activity
-1.06MAUDFY2025 · Jun 30, 2025Net Investing Cash Flow
-1.42MAUDFY2025 · Jun 30, 2025Common Stock Repurchase
-1.36MAUDFY2025 · Jun 30, 2025Other Financing Charges
-972.57KAUDFY2025 · Jun 30, 2025Net Financing Cash Flow
12.37MAUDFY2025 · Jun 30, 2025Shares Outstanding
465.54MSharesUpdated Aug 20, 2026Float Shares
442.72MSharesUpdated Aug 20, 2026% Held by Insiders
16.64%vs all stocks
% Held by Institutions
22.66%vs all stocks
Total Cash (MRQ)
56.76MAUD40.41M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1060AUDUpdated Aug 20, 2026Total Debt (MRQ)
10.24MAUD7.29M · vs all stocks (USD)
Current Ratio (MRQ)
6.58xvs Medical Devices peers
Book Value per Share (MRQ)
-0.0530AUDUpdated Aug 20, 2026Total Assets
94.81MAUD67.50M · vs all stocks (USD)
Total Current Assets
17.06MAUDFY2025 · Jun 30, 2025Total Liabilities
30.58MAUDFY2025 · Jun 30, 2025Total Non-current Assets
77.75MAUDFY2025 · Jun 30, 2025Total Non-current Liabilities
11.32MAUDFY2025 · Jun 30, 2025Total Current Liabilities
19.25MAUDFY2025 · Jun 30, 2025Cash
6.88MAUDFY2025 · Jun 30, 2025Cash & Cash Equivalents
6.88MAUDFY2025 · Jun 30, 2025Accounts Receivable
1.19MAUDFY2025 · Jun 30, 2025Inventory
919.63KAUDFY2025 · Jun 30, 2025Accounts Payable
1.87MAUDFY2025 · Jun 30, 2025Short-term Debt
1.09MAUDFY2025 · Jun 30, 2025Deferred Revenue
799.18KAUDFY2025 · Jun 30, 2025Other Current Liabilities
11.25MAUDFY2025 · Jun 30, 2025Long-term Debt
3.22MAUDFY2025 · Jun 30, 2025Other Non-current Liabilities
154.77KAUDFY2025 · Jun 30, 2025Common Stock (Book)
239.97MAUDFY2025 · Jun 30, 2025Retained Earnings
-182.11MAUDFY2025 · Jun 30, 2025Total Shareholders' Equity
64.24MAUD45.73M · vs all stocks (USD)
52-Week Low
0.4720AUDUpdated Aug 20, 202652-Week High
7.55AUDUpdated Aug 20, 202652-Week Change
651.43%vs all stocks
Beta
1.97xvs all stocks
50-Day MA
3.95AUDUpdated Aug 20, 2026200-Day MA
3.83AUDUpdated Aug 20, 2026Avg 10-Day Volume
5.26MSharesUpdated Aug 20, 2026Avg 30-Day Volume
5.52MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.4000AUDUpdated Aug 20, 2026Other Income / Expense
17.34MAUDFY2025 · Jun 30, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -929.7%, lower than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: -9.30Industry median: 0.07Industry P5: -0.52Peers compared: 59.00
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.74
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $4.14M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,136,698.617Global P5: 30,274,777.221
Market cap is $1.72B, above the global median of $1.15BNotable
Market cap (USD): 1,717,032,501.287Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule